



(51) International Patent Classification:

A61K 31/7105 (2006.01) A61K 38/17 (2006.01)
C07K 14/47 (2006.01) C12N 15/864 (2006.01)

(21) International Application Number:

PCT/US2019/054339

(22) International Filing Date:

02 October 2019 (02.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/740,162 02 October 2018 (02.10.2018) US

(71) Applicant: SANGAMO THERAPEUTICS, INC.
[US/US]; Point Richmond Tech Center, 501 Canal Blvd.,
Suite A100, Richmond, California 94804 (US).

(72) Inventors: RILEY, Brigit E.; c/o Sangamo Therapeu-
tics, Inc., Point Richmond Tech Center, 501 Canal Blvd.,
Suite A100, Richmond, California 94804 (US). ZEITLER,
Bryan; c/o Sangamo Therapeutics, Inc., Point Richmond
Tech Center, 501 Canal Blvd., Suite A100, Richmond, Cal-
ifornia 94804 (US).


(74) Agent: PASTERNAK, Dahna S.; Pasternak Patent Law,
1900 Embarcadero Road, Suite 211, Palo Alto, California
94303 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS AND COMPOSITIONS FOR MODULATION OF TAU PROTEINS

FIGURE 13



Baseline method: VEH + ZFP negative

(57) Abstract: The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*